indazoles has been researched along with Medulloblastoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Casati, A; Craveiro, RB; Dilloo, D; Ehrhardt, M; Olschewski, M; Pietsch, T; Schönberger, S; Velz, J | 1 |
| Craveiro, RB; Dilloo, D; Ehrhardt, M; Holst, MI; Pietsch, T | 2 |
| Craveiro, RB; Dilloo, D; Ehrhardt, M; Goetz, B; Olschewski, M; Pietsch, T; Velz, J | 1 |
4 other study(ies) available for indazoles and Medulloblastoma
| Article | Year |
|---|---|
The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma.
Topics: Antineoplastic Agents; Axitinib; Cell Line, Tumor; Cell Survival; Clone Cells; Drug Synergism; Humans; Indazoles; Medulloblastoma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Risk Factors; STAT3 Transcription Factor; Sulfonamides; United States; United States Food and Drug Administration | 2018 |
In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cerebellar Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Male; Medulloblastoma; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cerebellar Neoplasms; HEK293 Cells; Humans; In Vitro Techniques; Indazoles; Medulloblastoma; Mice; Phosphoinositide-3 Kinase Inhibitors; Random Allocation; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Humans; Indazoles; Medulloblastoma; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfonamides | 2017 |